A practical reference on peptide mapping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-09. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Novel technologies === Tecemotide is based on novel technologies, which may raise new regulatory issues that could delay or complicate regulatory approval. Additionally, as of 2013, the FDA had approved for commercial sale in the United States only one active vaccine designed to stimulate an immune response against cancer. Consequently, there is limited precedent for the successful development or commercialization of products based on these technologies in this area.
The first models of DNA evolution was proposed Jukes and Cantor in 1969. The Jukes-Cantor (JC or JC69) model assumes equal transition rates as well as equal equilibrium frequencies for all bases and it is the simplest sub-model of the GTR model. In 1980, Motoo Kimura introduced a model with two parameters (K2P or K80): one for the transition and one for the transversion rate. A year later, Kimura introduced a second model (K3ST, K3P, or K81) with three substitution types: one for the transition rate, one for the rate of transversions that conserve the strong/weak properties of nucleotides (
=== End of the war === One month after Đien Bien Phu, the composite Groupe Mobile 100 (GM100) of the French Union forces evacuated the An Khê outpost. They were ambushed by a larger Viet Minh force at the Battle of Mang Yang Pass on 24 June and again at the Battle of Chu Dreh Pass on 17 July, suffering heavy losses. This was the last battle of the war, as the Geneva accords were signed four days later, and the final ceasefire took effect on 11 August 1954.
Protein crystallization is the process of formation of a regular array of individual protein molecules stabilized by crystal contacts. If the crystal is sufficiently ordered, it will diffract. Some proteins naturally form crystalline arrays, like aquaporin in the lens of the eye. In the process of protein crystallization, proteins are dissolved in an aqueous environment and sample solution until they reach the supersaturated state. Different methods are used to reach that state such as vapor diffusion, microbatch, microdialysis, and free-interface diffusion. Developing protein crystals is a difficult process influenced by many factors, including pH, temperature, ionic strength in the crystallization solution, and even gravity. Once formed, these crystals can be used in structural biology to study the molecular structure of the protein, particularly for various industrial or medical purposes.
Sources: en.wikipedia.org
== Role in disease == Granzyme B has a normal concentration of 20-40 pg/ml in the blood plasma while retaining 70% activity and elevated concentrations of granzyme B are found in a number of disease states. Granzyme B can generate autoantigens by cleaving in disordered regions and linker regions of antigens exposing new epitopes and this can cause the development of autoimmune diseases. Granzyme B release with perforin from CD8+ T cells can cause heart and kidney transplant rejection through killing of allogeneic endothelial cells. The destruction of insulin producing β cells in pancreatic islets is mediated by T cells and granzyme B contributing to Type 1 Diabetes. Granzyme B can also mediate the death of cells after spinal cord injury and is found at elevated levels in rheumatoid arthritis. Chronic obstructive pulmonary disease (COPD) has been attributed to granzyme B secreted from NK and T cells causing the apoptosis of bronchial epithelial cells. Matrix destabilisation and remodelling by granzyme B is also linked to asthma pathogenesis. Granzyme B can kill melanocytes causing the skin condition vitiligo and granzyme B overexpression is found in contact dermatitis, lichen sclerosus and lichen planus cases. Cytotoxic cells expressing granzyme B have been identified close to hair follicles linking a possible role in hair loss. The ECM remodelling properties of granzyme B have also implicated its involvement in left ventricular remodelling, which increases the subsequent chances of myocardial infarction.
==== Cyber defense ==== Some scholars are concerned that AI will exacerbate the already imbalanced game between cyber attackers and cyber defenders. This would increase 'first strike' incentives and could lead to more aggressive and destabilizing attacks. In order to mitigate this risk, some have advocated for an increased emphasis on cyber defense. In addition, software security is essential for preventing powerful AI models from being stolen and misused. Recent studies have shown that AI can significantly enhance both technical and managerial cybersecurity tasks by automating routine tasks and improving overall efficiency. AI safety research has also examined defensive techniques for protecting machine learning systems from data poisoning attacks during training. In particular, label-flipping attacks can degrade model performance while remaining difficult to detect using conventional data validation methods. To address this risk, recent work has proposed model-agnostic detection pipelines that monitor learning behaviour and combine multiple detectors to identify suspicious training samples. Such approaches aim to strengthen cyber defense by improving the resilience and trustworthiness of AI systems operating in adversarial settings.
Isothermal titration calorimetry (ITC), is considered as the most quantitative technique available for measuring the thermodynamic properties of protein–protein interactions and is becoming a necessary tool for protein–protein complex structural studies. This technique relies upon the accurate measurement of heat changes that follow the interaction of protein molecules in solution, without the need to label or immobilize the binding partners, since the absorption or production of heat is an intrinsic property of virtually all biochemical reactions. ITC provides information regarding the stoichiometry, enthalpy, entropy, and binding kinetics between two interacting proteins. Microscale thermophoresis (MST), is a new method that enables the quantitative analysis of molecular interactions in solution at the microliter scale. The technique is based on the thermophoresis of molecules, which provides information about molecule size, charge and hydration shell. Since at least one of these parameters is typically affected upon binding, the method can be used for the analysis of each kind of biomolecular interaction or modification. The method works equally well in standard buffers and biological liquids like blood or cell-lysate. It is a free solution method which does not need to immobilize the binding partners. MST provides information regarding the binding affinity, stoichiometry, competition and enthalpy of two or more interacting proteins.
=== Measures of success === Success of liquid–liquid extraction is measured through separation factors and decontamination factors. The best way to understand the success of an extraction column is through the liquid–liquid equilibrium (LLE) data set. The data set can then be converted into a curve to determine the steady state partitioning behavior of the solute between the two phases. The y-axis is the concentration of solute in the extract (solvent) phase, and the x-axis is the concentration of the solute in the raffinate phase. From here, one can determine steps for optimization of the process.
Narrated by Tim Pigott-Smith, produced by Patrick Uden, directed by Sheila Hayman, made by Uden Associates 4 September The Tin Snail, about the Citroën 2CV; the 2CV was first introduced in October 1948; André Citroën saw himself as a French Henry Ford, and met American automotive industrialists in October 1931, including Henry Ford at the newly opened Ford Engineering Laboratory; the industrial historian Patrick Fridenson; Citroën lit up the Eiffel Tower in Citroën regalia, for publicity; but although André Citroën followed and admired Henry Ford, Citroën were innovative themselves, on 18 April 1934 the company launched the world's first mass-produced front-wheel drive car, the Citroën Traction Avant, when the company was narrowly avoiding bankruptcy; André Citroën died in 1935 and his company, being heavily in debt, was taken over by Édouard Michelin (brother of André Michelin); Fiat introduced its similar Fiat 500 in 1935, designed by Dante Giacosa; Ferdinand Porsche designed a new mass-produced car with rear air-cooled horizontally-opposed four-cylinder engine; France did not have such a car to Germany, so Citroën developed the Toute Petite Voiture (TPV), a proposal of Pierre Michelin - he brought in André Lefèbvre, who had designed the front-wheel-drive system of the Traction Avant and was a former aircraft engineer of Voisin, and led by Pierre-Jules Boulanger; Lefèbvre came from the aviation industry, and to save weight, made the car out of aluminium; the car had a torsion bar suspension, with eight torsion bars; Flaminio Bertoni, an Italian, was head of exterior design at Citroën, from 1932 to 1964; Carl Olsen, head of Citroën exterior design from 1982 to 1987; Alex Moulton, the Cambridge-educated mechanical engineer, who designed the suspension for the innovative Mini, in the late 1950s; Lucien Gerard, from Talbot, and Walter Becchia, who designed the two-cylinder water-cooled horizontally opposed engine. Narrated by Peter Jones, produced by Patrick Uden, directed by Jeremy Llewellyn-Jones, made by Uden Associates 11 September Deep Trouble, about the North Sea oil industry; the beginning of 1986 saw peak production of North Sea oil; finding new oil reserves would be from deeper oil fields, that cost more money to extract; at the same time the oil price plummeted, with over 15,000 job losses in the British oil industry by the end of 1986; Vickers Ltd entered the oil exploration industry; submersible craft were helping exploration of oil, with remotely operated craft becoming important. Narrated by Martin Jarvis, produced by Patrick Uden, directed by Paul Fabricius, made by Uden Associates 18 September What They Don't Tell You When They Sell You a Computer, about professionalism in the computer hardware industry; Eddy Shah from the Today newspaper, and their new unreliable computer system; Brian Wilson of First Computer believed that the computer hardware retailing industry were largely unprofessional unscrupulous cowboys; the National Computing Centre (NCC) was set up by the government in 1966, to provide advice; BP opened its own Microshop, to circumvent the cowboys, and assist with technical jargon, and connecting devices; due to warp-drive technical obsolescence in the 1980s, yesterday's computers rapidly lost all total value; Iain Callaghan, operations director of John Menzies newspaper distribution business, and how computer databases could process newsagents' daily orders much quicker and reliably; Geoff Dalby, head of data at Woolwich Equitable Building Society, which had called off a merger with the Nationwide Building Society, as their computer systems would not work together; greater computer automation of the personal finance industry could lead to much less day-to-day contact with individual customers; David Bailey of Phillips & Drew. Narrated by Miriam Margolyes, produced by Michael Blakstad, directed by Catherine Robins, made by Workhouse Productions 25 September Precisely in Profit, about manufacturing to exact margins. Produced by Glyn Jones, directed by Eben Wilson, made by Quanta 2 October Now Eat This, about snack foods. Produced by Edward Poulter, directed by Mike Tomlinson, made by London Scientific Films 9 October Growing up with Rockets, a personal, and underreported, view of early elementary rocketry from 1950, starting with captured German V-2 rockets; the former 1970 class of Cocoa Beach High School; failed launches would land in the Banana River; NASA was formed in July 1958, in a coherent response to the Russian launches in 1957; the President visits Cocoa Beach to celebrate the US getting a man to orbit the Earth in February 1962; the nearby Patrick Air Force Base; Syncom 3 was launched on 19 August 1964, the world's first geostationary communication satellite, on a Delta rocket; the minutes leading up to the first launch of STS-1 in April 1981. Directed and a first hand account of Nancy Yasecko, produced by Patrick Uden, made by Uden Associates 16 October Shock Trauma, about the Baltimore Shock Trauma Center (R Adams Cowley Shock Trauma Center). A Canadian production, produced by Patrick Uden, made by National Film Board of Canada and Uden Associates 23 October Drink Drive and Murder; it featured two court cases in the US, where a 33 year old killed a couple in their 20s, and a 17 year old who killed a couple of teenagers, and a Californian drink-drive reform centre; in some US states, if you kill when drunk, the charge is murder. A Canadian production, made by Uden Associates and the National Film Board of Canada 30 October The New Magicians, about film special effects; Gertie the Dinosaur in 1914 and The Sinking of the Lusitania in 1918; the King Kong (1933 film); the 1950s and 1960s saw modest increases in special effects, notably Forbidden Planet in 1956, until 2001: A Space Odyssey was important in 1968; another important film was Star Wars (film) in 1977, along with Close Encounters of the Third Kind, Tron in 1982 and The Last Starfighter in 1984. A Canadian production, produced by Ken McKay, made by TV Ontario 6 November Pioneers of the Future, about the development of microchips, such as Steve Dorsey, who invented the word processor. A Canadian production, produced by Ken McKay, made by Uden Associates and TV Ontario 13 November Skyscraper, about Old Madison Square Gardens and skyscrapers in Chicago and New York; Arthur Nusbaum; architect Stanley Tigerman; the tallest masonry-only building was 16 storeys high; the Great Chicago Fire in October 1871, which allowed different, and stronger, structures of building to be built instead; the 1902 Flatiron Building; architect Jack Hartray; mechanical engineer George Strakosch; the 1908 600-feet Singer Building; the 1912 800-feet Woolworth Building; the 1915 Equitable Building (Manhattan); the 1930 900-feet Chrysler Building; the 1931 1250-feet Empire State Building; mechanical engineer David Stillman; structural engineer Charles Thornton; architect Robert Sobel; structural engineer Leslie E. Robertson; civil engineer Alan Garnett Davenport of the University of Western Ontario; architect Bruce Graham; architect Harry Weese; architect Moshe Safdie. Narrated by William Woollard, produced by Nicola Glucksmann, directed by Karl Sabbagh, made by InCA
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.